To Change or Not to Change: Perceptions and Experiential Knowledge of Tennis Coaches When Modifying Grip Technique.

The purpose of this study was to explore the experiential knowledge of tennis coaches as it related to the development of grip positions in tennis athletes. Accredited tennis coaches (n = 11) completed semi-structured interviews consisting of open-ended questions about their coaching background, the importance of grip positions compared with other areas of foundational development, and their opinions on using physically-constraining tools (PCTs). Two major themes, "Grip positions are an adaptive skill" and "Why and how do I modify an athlete's grip?", were identified.

EXPOSURE TO THE POLYCHLORINATED BIPHENYL MIXTURE AROCLOR 1254 ELICITS NEUROLOGICAL AND CARDIAC DEVELOPMENTAL EFFECTS IN EARLY LIFE STAGE ZEBRAFISH (Danio rerio).

The goal of this study was to compare the bioaccumulation of the PCB mixture Aroclor 1254 in zebrafish to cardiac and neurologic outcomes. The establishment of effect concentrations (ECs) for cardiac and neurotoxic effects of PCBs in early life stage fish is challenging due to a lack of measured PCB concentrations in test media (e.g.

Characteristics and management of eosinophilic esophagitis in Australasian children: a decade of experience.

Background: The frequency of EoE has been increasing in Northern Hemisphere cohorts, yet there is a scarcity of data in our region. Regional climatic factors, and lifestyle habits may influence the presentation of EoE, and appropriate management is crucial to prevent complications. WIth this is mind we undertook the first comprehensive multisite study of EoE in Australasian children.

Developing and disseminating an electronic penicillin allergy de-labelling tool using the model for improvement framework.

Background: Many clinicians feel uncomfortable with de-labelling penicillin allergies despite ample safety data. Point of care tools effectively support providers with de-labelling. This study's objective was to increase the number of providers intending to pursue a penicillin oral challenge by 15% by February 2023.